Slingshot members are tracking this event:

AstraZeneca's (AZN) ARCTIC trial evaluating durvalumab, tremelimumab, and combination durva + treme against the standard of care for lung cancer patients data expected in November 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AZN Community voting in process

Additional Information

Additional Relevant Details Update on Apr 26 2017: The clinical study testing AstraZeneca’s experimental immunotherapy drugs in lung cancer patients who have already received at least two previous treatments will take longer than initially expected to produce results.

A company spokeswoman said the delay was because the trial had not yet observed enough clinical events in patients.
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Durvalumab, Tremelimumab, Durva + Treme, Lung Cancer, Arctic